Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America.

Autor: de la Cruz C; Clínica Dermacross, Santiago, Chile., de Carvalho AV; Dermatology Ambulatory, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil., Dorantes GL; Mexican Association Against Psoriasis, Mexico City, Mexico., Londoño Garcia AM; Department of Dermatology of CES University, Medellin, Colombia., Gonzalez C; Clínica Universitaria Colombia, Bogotá DC, Colombia., Maskin M; Department of Dermatology, CEMIC, Buenos Aires, Argentina., Podoswa N; Department of Dermatology, HGR1 IMSS, Mexico City, Mexico., Redfern JS; Redfern Strategic Medical Communications, Springtown, Texas, USA., Valenzuela F; Department of Dermatology, University of Chile and Probity Medical Research, Santiago, Chile., van der Walt J; International Psoriasis Council, St Louis, Missouri, USA., Romiti R; Department of Dermatology, Hospital das Clínicas University of São Paulo (USP), São Paulo, Brazil.

Publikováno v: The Journal of dermatology [J Dermatol] 2017 Jan; Vol. 44 (1), pp. 3-12. Date of Electronic Publication: 2016 Jul 27.

Control of Moderate-to-Severe Plaque Psoriasis with Efalizumab: 24-Week, Open-Label, Phase IIIb/IV Latin American Study Results.

Autor: Stengel FM, Petri V, Campbell GA, Dorantes GL, López M, Galimberti RL, Valdez RP, de Arruda LF, Guerra MA, Chouela EN, Licu D

Publikováno v: Archives of drug information [Arch Drug Inf] 2009 Dec; Vol. 2 (4), pp. 71-78.